
|Videos|February 1, 2023
Advice for Community Oncologists who Treat Patients with NSCLC
Author(s)Mark Socinski, MD, Joshua K. Sabari, MD
Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































